CIPLA LTD. - Updates on Subsidiary

Cipla Ltd has informed BSE that Meditab Specialities Private Limited ("MSPL"), a wholly owned subsidiary of the Company, has acquired 75% stake in Mabpharm Private Limited ("Mabpharm").<br/><br/>The Company was earlier holding 25% stake in Mabpharm. Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100% subsidiary of the Company. Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases.